Follow
Christophe LMJ Verlinde
Title
Cited by
Cited by
Year
Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase
FS Buckner, CL Verlinde, AC La Flamme, WC Van Voorhis
Antimicrobial agents and chemotherapy 40 (11), 2592-2597, 1996
6031996
Structure-based drug design: progress, results and challenges
CLMJ Verlinde, WGJ Hol
Structure 2 (7), 577-587, 1994
3661994
High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design
E Fan, Z Zhang, WE Minke, Z Hou, CLMJ Verlinde, WGJ Hol
Journal of the American Chemical Society 122 (11), 2663-2664, 2000
3622000
Genomic-scale prioritization of drug targets: the TDR Targets database
F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ...
Nature reviews Drug discovery 7 (11), 900-907, 2008
3552008
Glycolysis as a target for the design of new anti-trypanosome drugs
CLMJ Verlinde, V Hannaert, C Blonski, M Willson, JJ Périé, ...
Drug Resistance Updates 4 (1), 50-65, 2001
3202001
Missense mutations in the regulatory domain of PKCγ: a new mechanism for dominant nonepisodic cerebellar ataxia
DH Chen, Z Brkanac, LMJC Verlinde, XJ Tan, L Bylenok, D Nochlin, ...
The American Journal of Human Genetics 72 (4), 839-849, 2003
2982003
Macromolecular Crystallography and Medicine
WGJ Hol, CLMJ Verlinde
International Tables for Crystallography F, 10-43, 2006
291*2006
Five members of a novel Ca2+-binding protein (CABP) subfamily with similarity to calmodulin
F Haeseleer, I Sokal, CLMJ Verlinde, H Erdjument-Bromage, P Tempst, ...
Journal of Biological Chemistry 275 (2), 1247-1260, 2000
2832000
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors
KK Ojo, ET Larson, KR Keyloun, LJ Castaneda, AE DeRocher, ...
Nature structural & molecular biology 17 (5), 602-607, 2010
1912010
Rational modification of a candidate cancer drug for use against Chagas disease
JM Kraus, CLMJ Verlinde, M Karimi, GI Lepesheva, MH Gelb, FS Buckner
Journal of medicinal chemistry 52 (6), 1639-1647, 2009
1772009
AB5 toxins: structures and inhibitor design
E Fan, EA Merritt, CLMJ Verlinde, WGJ Hol
Current opinion in structural biology 10 (6), 680-686, 2000
1772000
Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase
AM Aronov, S Suresh, FS Buckner, WC Van Voorhis, CLMJ Verlinde, ...
Proceedings of the National Academy of Sciences 96 (8), 4273-4278, 1999
1761999
Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin
Z Zhang, EA Merritt, M Ahn, C Roach, Z Hou, CLMJ Verlinde, WGJ Hol, ...
Journal of the American Chemical Society 124 (44), 12991-12998, 2002
1632002
Alternatively spliced isoforms of the human constitutive androstane receptor
SS Auerbach, R Ramsden, MA Stoner, C Verlinde, C Hassett, ...
Nucleic acids research 31 (12), 3194-3207, 2003
1562003
Adenosine Analogues as Selective Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase of Trypanosomatidae via Structure-Based Drug Design
JC Bressi, CLMJ Verlinde, AM Aronov, ML Shaw, SS Shin, LN Nguyen, ...
Journal of medicinal chemistry 44 (13), 2080-2093, 2001
1552001
Three-dimensional structure of the diphtheria toxin repressor in complex with divalent cation co-repressors
X Qiu, CLMJ Verlinde, S Zhang, MP Schmitt, RK Holmes, WGJ Hol
Structure 3 (1), 87-100, 1995
1491995
Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii
RC Murphy, KK Ojo, ET Larson, A Castellanos-Gonzalez, BGK Perera, ...
ACS medicinal chemistry letters 1 (7), 331-335, 2010
142*2010
Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana: implications for structure-based drug design and a new position for the …
H Kim, IK Feil, CLMJ Verlinde, PH Petra, WGJ Hol
Biochemistry 34 (46), 14975-14986, 1995
1401995
Structure-based exploration of the ganglioside GM1 binding sites of Escherichia coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists
WE Minke, C Roach, WGJ Hol, CLMJ Verlinde
Biochemistry 38 (18), 5684-5692, 1999
1381999
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery
JM Kraus, HB Tatipaka, SA McGuffin, NK Chennamaneni, M Karimi, J Arif, ...
Journal of medicinal chemistry 53 (10), 3887-3898, 2010
1372010
The system can't perform the operation now. Try again later.
Articles 1–20